. 2015 Oct 26;15:804. doi: 10.1186/s12885-015-1830-8

Table 1.

Clinicopathological parameters and survival analysis in 102 primary UPS tumors

					P
Variable	Group	No.	(%)	Analyzed groups	Overall survival	Event-free survival
Sex	Male	45	44.1		0.3077	0.1815
Sex	Female	57	55.9		0.3077	0.1815
Age (17 ~ 93, mean: 62)	<62	53	52		0.3714	0.1518
Age (17 ~ 93, mean: 62)	≧62	49	48		0.3714	0.1518
Size	<5 cm	35	34.3		0.0058^a	0.0008^a
	≧5 cm	56	54.9
	N/A	11	10.8
Location	Superficial	42	41.2		0.0154^a	0.0193^a
	Deep	54	52.9
	NA	6	5.9
Chemotherapy	Yes	20	19.6		0.5761	0.9270
	No	30	29.4
	NA	52	51.0
Surgical margin	Positive	18	17.6		0.3069	0.9937
	Negative	45	44.1
	NA	39	38.3
Metastasis	+	28	27.5		<0.0001^a	<0.0001^a
Metastasis	-	74	72.5		<0.0001^a	<0.0001^a
Reccurence	+	16	15.7		0.9212	<0.0001^a
Reccurence	-	86	84.3		0.9212	<0.0001^a
Necrosis	0, score 0	58	56.9	Score 0 vs others	0.0011^a	0.0101^a
	<50 %, score 1	31	30.4	Score 1 vs score 2	0.464	0.6221
	≧50 %, score 2	13	12.7	Score 2 vs others	0.0344^a	0.2112
Mitosis	0–9/10 HPF, score 1	53	52	Score 1 vs others	0.0003^a	0.0005^a
	10–19/10 HPF, score 2	28	27.4	Score 2 vs score 3	0.0291^a	0.4872
	20≧/10 HPF, score 3	21	20.6	Score 3 vs others	<0.0001^a	0.0077^a
MIB-1 LI	<10 %	20	26.7		0.0569	0.0533
	≧10 %	50	66.7
	NA	5	6.6
FNCLCC	2	64	62.7		<0.0001^a	00002^a
FNCLCC	3	38	37.3		<0.0001^a	00002^a
AJCC 7th ed	II	59	57.8	Stage II vs others	<0.0001^a	<0.0001^a
	III	15	14.7	Stage III vs IV	0.0614	<0.0001^a
	IV	28	27.5

AJCC American Joint Committee on Cancer, FNCLCC French Federation of Cancer Centers, HPF high-power fields, LI labeling index, N/A not available, No. number of patients. The Fisher exact test or the log-rank test was used if not indicated otherwise

^aStatistically significant